Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
  • Patent number: 10358462
    Abstract: The present invention relates to a method for the preparation of a solution of immunoglobulins based on an initial solution of immunoglobulins with a purity greater than or equal to 96% in the presence of a polyether or polymer of glycol, characterized in that it comprises the steps of: a) adding caprylic acid or salts of the same to the initial solution; b) adjusting the pH of the solution obtained in step a); c) incubating the solution obtained in step b) for the time and at a temperature necessary for the inactivation of enveloped viruses; d) performing a step of ultrafiltration/diafiltration on the solution obtained in step c).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 23, 2019
    Assignee: INSTITUTO GRIFOLS, S.A.
    Inventors: Pere Ristol Debart, Salvador Grancha Gamon, Juan Ignacio Jorquera Nieto, Maria Mercedes Faro Tomas, Nuria Jorba Grifols
  • Patent number: 10188713
    Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided. In general, one aspect of this document features a composition comprising, or consisting essentially of, nucleic acid encoding HIF-2a, SOX-10, C-MYC, and TYRP-1, wherein the composition comprises less than 100 separate nucleic acid molecules.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: January 29, 2019
    Assignees: Mayo Foundation for Medical Education and Research, University of Leeds
    Inventors: Richard G. Vile, Timothy J. Kottke, Jill M. Thompson, Jose S. Pulido, Alan A. Melcher, Peter Selby
  • Patent number: 10183984
    Abstract: A method for extracting recombinant human serum albumin (rHSA) from transgenic rice grain is provided, comprising the steps of: 1) grinding dehusked rice containing rHSA into milled rice grain with a fineness of 80˜120 mesh, which is mixed with a extraction buffer in a w/v ratio of 1:5, then extracting at 55˜60° C. for 1˜3 hours to obtain mixture I; said extraction buffer comprises 10˜30 mM phosphate buffer, 10˜20 mM sodium acetate, 15˜30 mM ammonium sulfate and 5˜20 mM sodium caprylate and has a pH of 6.5˜8; 2) adjusting the pH of mixture I to 4.0˜4.5, followed by precipitating at room temperature for 3˜12 hours to obtain mixture II; 3) filtering the mixture II and collecting the filtrate, to obtain a solution containing high concentration of rHSA. The concentration of rHSA in the resultant solution is 650˜660 ?g/mL, which increases by 1.15 times comparing to the extraction amount before improvement, and the amount of non-target protein is reduced by 2.46 times.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 22, 2019
    Assignee: Healthgen Biotechnology Corp.
    Inventors: Daichang Yang, Yang He, Guangfei Li
  • Patent number: 10179138
    Abstract: The present invention relates to a pharmaceutical composition comprising (a) 7?-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance ?-hydroxycholesterol, which is poorly soluble in water.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: January 15, 2019
    Assignee: IMMUNOPHARM AG
    Inventors: Werner Bieberschulte, Christine Grimm, Rohan Charles Fernando
  • Patent number: 10016533
    Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 10, 2018
    Inventor: Meng Chen
  • Patent number: 9855325
    Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 2, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Patent number: 9603978
    Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 28, 2017
    Inventor: Meng Chen
  • Patent number: 9562900
    Abstract: Specific DNA sequences for binding various foodborne and waterborne pathogens and biotoxins are described. Each of these sequences can function in varying assay and sensor formats with varying degrees of success.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: February 7, 2017
    Assignee: OTC Biotechnologies, LLC
    Inventor: John G. Bruno
  • Patent number: 9506920
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 29, 2016
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund
  • Patent number: 9149541
    Abstract: A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: October 6, 2015
    Assignee: NOVARTIS AG
    Inventors: Roberto Adamo, Martin Allen, Francesco Berti, Elisa Danieli, Qi-Ying Hu
  • Publication number: 20150147325
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150147324
    Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are a Fe polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: John C. Timmer, Brendan P. Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Patent number: 9023797
    Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: May 5, 2015
    Assignee: Grifols, S.A.
    Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
  • Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Publication number: 20150104818
    Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Publication number: 20150094267
    Abstract: The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 2, 2015
    Inventors: Kim D. Vandegriff, Ashok Malavalli, Gnel Mkrtchyan
  • Publication number: 20150087586
    Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.
    Type: Application
    Filed: March 25, 2013
    Publication date: March 26, 2015
    Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
  • Patent number: 8986688
    Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide, a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: March 24, 2015
    Assignee: InhibRx, LLC
    Inventors: John Timmer, Brendan Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
  • Patent number: 8980266
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: March 17, 2015
    Assignee: InhibRx, LLC
    Inventors: Brendan Eckelman, John Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150072919
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
  • Publication number: 20150065687
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 5, 2015
    Inventor: Karen Ann Delahay
  • Publication number: 20150050713
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: July 25, 2014
    Publication date: February 19, 2015
    Inventors: Michael P. Malakhov, Fang Fang
  • Publication number: 20150051375
    Abstract: A bonding method is provided for gold nanoparticles (GNPs). GNPs are bonded with diethylenetriamine pentaacetic acid (DTPA). GNPs have high bio-compatibility and high surface area. Hence, the present invention uses GNPs as carriers for diagnosing and treating cancer.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 19, 2015
    Applicant: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.
    Inventors: Chun-Chia Cheng, Shiau-Shiun Guan
  • Publication number: 20150045302
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Angelo Corti, Flavio Curnis
  • Publication number: 20150038681
    Abstract: A method of preparing a product, preferably in the form of a functionalized high molecular weight component such as, for example, a functionalized protein includes passing a first liquid comprising a component A along one side of a semi-permeable membrane and passing a second liquid comprising a component B along another, preferably opposing, side of the membrane, wherein the membrane excludes passage of component A but allows passage of component B, and after passage of component B through the membrane, a chemical reaction takes place between component A and component B, preferably with the formation of covalent bonds.
    Type: Application
    Filed: August 4, 2014
    Publication date: February 5, 2015
    Inventors: Juergen Mollenhauer, Heinz W. Joseph, Helmut Wurst
  • Patent number: 8946167
    Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: February 3, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
  • Publication number: 20150031604
    Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
  • Publication number: 20150030594
    Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
  • Publication number: 20150024456
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 22, 2015
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 8933199
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 13, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
  • Patent number: 8927694
    Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: January 6, 2015
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Charlotte McDonagh, Michael Feldhaus, Alexandra Huhalov
  • Publication number: 20140370046
    Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.
    Type: Application
    Filed: May 9, 2012
    Publication date: December 18, 2014
    Applicant: Biothera, Inc.
    Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
  • Patent number: 8906633
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20140357564
    Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.
    Type: Application
    Filed: February 14, 2013
    Publication date: December 4, 2014
    Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
  • Publication number: 20140349929
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 27, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Patent number: 8889830
    Abstract: A novel hemoglobin-albumin complex which has high stability of the oxygenated form, has high biocompatibility, and is easily prepared (synthesized), and an artificial plasma expander and an artificial oxygen carrier containing the complex are provided. The hemoglobin-albumin complex of the invention is characterized by having hemoglobin as the core, and albumin as the shell bound via a crosslinker to the above hemoglobin. Also, the artificial oxygen carrier of the invention is characterized by containing the hemoglobin-albumin complex of the invention.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: November 18, 2014
    Assignee: Chuo University
    Inventors: Teruyuki Komatsu, Daiki Tomita
  • Publication number: 20140322306
    Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 30, 2014
    Inventors: Mark Eccleston, Satu Vainikka, George Steven Morris
  • Publication number: 20140323688
    Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 30, 2014
    Inventor: Andrew Lees
  • Publication number: 20140315816
    Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
  • Publication number: 20140316110
    Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 23, 2014
    Inventor: Andrew Lees
  • Publication number: 20140315817
    Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.
    Type: Application
    Filed: November 18, 2012
    Publication date: October 23, 2014
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Eric Steven Furfine, Amy Jada Andreucci, Thomas M. Barnes
  • Publication number: 20140316111
    Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyanoimidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 23, 2014
    Inventor: Andrew Lees
  • Patent number: 8865647
    Abstract: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Helle Naver, Svend Havelund, Peter Madsen
  • Publication number: 20140309163
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 16, 2014
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Martin J. Corbett, Alexander T. Kozhich
  • Patent number: 8859499
    Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: October 14, 2014
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California
    Inventors: Seetharama A. Acharya, Marcos Intaglietta
  • Patent number: 8859724
    Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: October 14, 2014
    Assignee: B. Braun Melsungen AG
    Inventors: Bernd H. Meier, Nele Meier
  • Publication number: 20140302554
    Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 9, 2014
    Inventors: Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li
  • Publication number: 20140302618
    Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 9, 2014
    Applicant: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Patent number: 8853154
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 7, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.